Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

7,980 public trials 715 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

NCT00256607

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +4 more
Locations
  • Carl T. Hayden VA Medical Center Phoenix, Arizona, United States
  • Southern Arizona VA Health Care System, Tucson Tucson, Arizona, United States
  • VA Medical Center, Long Beach Long Beach, California, United States
  • VA San Diego Healthcare System, San Diego San Diego, California, United States
View Trial Details
Completed

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

NCT00819091

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.35.10002 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1218.35.10001 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 1218.35.10016 Boehringer Ingelheim Investigational Site National City, California, United States
  • 1218.35.10017 Boehringer Ingelheim Investigational Site Fort Lauderdale, Florida, United States
View all 45 locations
View Trial Details
Completed

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

NCT01012037

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.62.32003 Boehringer Ingelheim Investigational Site De Pinte, Belgium
  • 1218.62.32008 Boehringer Ingelheim Investigational Site Kortenaken, Belgium
  • 1218.62.32009 Boehringer Ingelheim Investigational Site Kumtich, Belgium
  • 1218.62.32005 Boehringer Ingelheim Investigational Site Massemen-Wetteren, Belgium
View all 84 locations
View Trial Details
Completed

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

NCT00740051

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.50.10009 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1218.50.10011 Boehringer Ingelheim Investigational Site Peoria, Arizona, United States
  • 1218.50.10013 Boehringer Ingelheim Investigational Site Greenbrae, California, United States
  • 1218.50.10016 Boehringer Ingelheim Investigational Site Harbor City, California, United States
View all 53 locations
View Trial Details
Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

NCT00935220

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.55.0006 Boehringer Ingelheim Investigational Site Cypress, California, United States
  • 1218.55.0008 Boehringer Ingelheim Investigational Site DeLand, Florida, United States
  • 1218.55.0004 Boehringer Ingelheim Investigational Site Miami, Florida, United States
  • 1218.55.0005 Boehringer Ingelheim Investigational Site Baltimore, Maryland, United States
View Trial Details

Related conditions